SpectraCure AB (SPEC) AI Stock Analysis

• Market Cap: kr43.58M
• Dividend Yield: N/A
• Average Volume (3M): 1.15M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.68
• Revenue Growth: N/A
• EPS Growth: -108.64%
• Country: SE
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.09
• Shares Outstanding: 401,334,320
• 10 Day Avg. Volume: 1,242,664
• 30 Day Avg. Volume: 1,152,681
• PEG Ratio: -0.75
• Price to Book (P/B): 2.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: kr0.11 ▼(-41.67% Downside)

The score is held down primarily by weak financial performance—minimal revenue, widening losses, and continued negative operating/free cash flow—alongside very bearish technicals (below all major moving averages with negative MACD). Low leverage helps reduce balance-sheet risk, but valuation is difficult to justify on earnings due to ongoing losses.

Positive Factors

Low Financial Leverage

Very low debt relative to equity provides durable financial flexibility for a clinical-stage medical device company. Low leverage reduces refinancing and interest burden risk, preserving optionality to fund trials, partnerships or commercialization without immediate debt pressure.

Focused clinical-stage product platform

A clear, differentiated platform (treatment planning + light-delivery) targeting solid tumors offers structural product-market fit. The platform approach supports reuse across indications and strengthens long-term commercial potential if clinical efficacy and regulatory approval are demonstrated.

Improving free cash flow trend

Year-over-year improvement in free cash flow, even from negative levels, signals operational traction and improving capital efficiency. If sustained, this trend can lengthen runway, reduce external funding needs, and indicate management progress in cost discipline and execution.

Negative Factors

Minimal revenue base

Negligible revenues mean commercialization is not yet proven and operating leverage is absent. The business remains dependent on development milestones and funding; lack of recurring sales limits durable cash generation and makes long-term forecasts highly binary.

Persistent cash burn

Sustained negative operating and free cash flows require ongoing external capital to sustain R&D and commercialization. Continued cash burn erodes reserves and increases dilution or financing risk, constraining strategic choices and slowing progress toward self-sustaining operations.

Widening losses and eroding equity

Materially larger recent losses and a halving of equity over years weaken the capital base and the firm's ability to fund clinical programs internally. Continued erosion reduces strategic flexibility and raises the bar for achieving profitability without significant external support.

SpectraCure AB Business Overview & Revenue Model

Company Description

SpectraCure AB (SPEC) is a medical technology company operating primarily in the field of cancer treatment. The company specializes in developing and commercializing innovative systems for photodynamic therapy (PDT), a minimally invasive treatment approach that uses light-sensitive drugs to target and destroy cancer cells. SpectraCure's core product is its proprietary interstitial PDT (IPDT) system, designed to treat solid tumors such as prostate cancer. The company is committed to advancing cancer care by providing effective and less invasive treatment options.

How the Company Makes Money

SpectraCure AB generates revenue primarily through the development, sales, and licensing of its proprietary photodynamic therapy systems. The company's IPDT system is designed for use in clinical settings, and revenue is earned from selling the system to hospitals and clinics. Additional revenue streams may include service agreements, maintenance contracts, and the sale of consumables required for treatment procedures. SpectraCure may also engage in strategic partnerships with healthcare providers and research institutions to expand the adoption of its technology, potentially leading to collaborative revenue-sharing arrangements. The company's income is influenced by the adoption rate of its technology, clinical trial outcomes, and regulatory approvals that permit market expansion.

SpectraCure AB Financial Statement Overview

Summary

SpectraCure AB exhibits financial distress with consistent net losses, negative margins, and cash flow challenges despite some revenue growth. The high equity ratio and low debt offer some stability, but operational inefficiencies and negative profitability metrics pose significant risks.

Income Statement

SpectraCure AB has shown a significant increase in total revenue from 2023 to 2024, but this growth is overshadowed by consistently high net losses over the years. Gross profit margin has improved, indicating better cost management, but negative EBIT and EBITDA margins highlight ongoing operational struggles. Revenue growth is positive, yet the persistent negative net profit margin signals financial instability.

Balance Sheet

SpectraCure AB maintains a high equity ratio, suggesting financial stability and a low reliance on debt. However, the company has experienced declining stockholders' equity over recent years. Despite a low debt-to-equity ratio, the negative net income affects the return on equity, indicating inefficiencies in generating returns from equity investments.

Cash Flow

The cash flow statement reflects challenges in achieving positive cash flows, with negative operating and free cash flows throughout. The free cash flow to net income ratio remains concerning, as cash outflows exceed inflows. Operating cash flow relative to net income suggests difficulties in converting sales into actual cash, hampering financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	318.00K	539.00K	0.00	1.21K
Gross Profit	-20.82M	9.77M	-9.22M	3.58M	1.39M	2.35M
EBITDA	-21.67M	-20.42M	-20.97M	-22.27M	-20.43M	-12.88M
Net Income	-53.17M	-23.00M	-20.44M	-25.33M	-23.34M	-15.41M
Balance Sheet
Total Assets	111.25M	121.00M	144.83M	162.42M	190.52M	210.53M
Cash, Cash Equivalents and Short-Term Investments	25.51M	18.27M	56.95M	93.18M	129.69M	157.24M
Total Debt	3.40M	5.14M	6.72M	2.70M	4.90M	5.36M
Total Liabilities	10.14M	14.15M	14.97M	12.12M	14.84M	13.32M
Stockholders Equity	101.11M	106.86M	129.86M	150.30M	175.68M	197.22M
Cash Flow
Free Cash Flow	-38.65M	-37.10M	-34.45M	-33.08M	-27.09M	-19.99M
Operating Cash Flow	-25.90M	-21.83M	-18.68M	-22.96M	-18.60M	-9.40M
Investing Cash Flow	-16.70M	-15.28M	-15.56M	-11.35M	-8.49M	-10.58M
Financing Cash Flow	40.29M	-1.57M	-1.99M	-2.20M	-453.00K	123.02M

SpectraCure AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.18
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPEC, the sentiment is Negative. The current price of 0.18 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.17, and below the 200-day MA of 0.28, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 22.77 is Positive, neither overbought nor oversold. The STOCH value of 9.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SPEC.

SpectraCure AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SDOS	50 Neutral	kr65.28M	-47.31	―	―	―	―
SCIB	44 Neutral	kr181.41M	-0.85	-253.54%	―	36.15%	26.67%
HEART	43 Neutral	kr138.96M	-0.84	―	―	―	―
SPEC	42 Neutral	kr43.58M	-0.52	-50.21%	―	―	-108.64%
CMH	42 Neutral	kr2.08M	-0.05	―	―	―	―
LXB	38 Underperform	kr57.27M	-2.62	-60.20%	―	163.12%	30.50%